Achilles Therapeutics has been started in the UK using research from UCL (University College London) and the Francis Crick Institute.
Syncona, an investment unit of medical charity Wellcome Trust, and UK-based impact investor Cancer Research Technology (CRT) through its CRT Pioneer Fund and the UCL Technology Fund led the £13.2m ($17.5m) funding.
Achilles Therapeutics will design therapies to target truncal tumour neo-antigens – unique flags to the immune system present on the surface of every cancer cell, which were first discovered by Cancer…
